The deal also provides Sobi with the right to participate in payments from the US profits or losses for new medicine MEDI8897 in development for RSV-induced LRTI As
The post Sobi acquires Synagis US rights from AstraZeneca appeared first on Pharmaceutical Business review.
Original Article: Sobi acquires Synagis US rights from AstraZeneca